Pearls and paradigms in Infective Keratitis

Acharya Manisha*, Farooqui Javed Hussain*, Jain Shikha**, Mathur Umang*
*Dr. Shroff's Charity Eye Hospital, New Delhi, India
**Ram Manohar Lohia Hospital, New Delhi, India

Correspondence to: Manisha Acharya, MD, MBBS, MS, In-Charge, Eye Bank, Consultant, Cornea, Cataract and Refractive Surgery, Dr. Shroff’s Charity Eye Hospital, 5027, Kedarnath Marg, Daryaganj, New Delhi, 110002, India, Phone: +91-9810136933, E-mail: manisha28dr@gmail.com

Accepted: April 25th, 2019

Abstract
Infective Keratitis is a commonly encountered sight-threatening ocular emergency. In developing countries, it is a major cause of corneal blindness. Empirical treatment without microbiological work up often leads to treatment failure. Indiscriminate use of steroid antibiotic combination worsens the situation and makes further management challenging. The correct line of management can be potentially sight saving for both the ophthalmologist and the patient. This article on Infective keratitis has been written keeping best practices and protocols in mind. In a very simple and concise form, it focuses on the salient features of clinical presentation of infective keratitis and the stepwise approach to subsequent management in a patient. It explains in detail the way to perform corneal scraping, the importance of the same and further management based on microbiologically proven result. The management part includes indications and methods for medical as well as surgical intervention. We aimed to share our experience in the management of patients presenting with infective keratitis in the clinic.

Keywords: infective keratitis, bacterial, management, microbiology, staining, culture, treatment

Natural Ocular Defenses

The eye is protected from all sides by the projecting bony orbital rim, and additionally by the eyelids [1]. A healthy tear film with a normal lacrimal drainage system serves as another defense, washing away desquamated epithelial cells, foreign bodies and microbes [2].

The epithelia of the conjunctiva and the cornea act as mechanical barriers to infection [3]. Also, the conjunctiva has associated lymphoid tissue, termed CALT (conjunctiva associated lymphoid tissue), wherein immunity is initiated by exposure to exogenous antigens by the production of IgA antibodies [4].

Risk Factors for Infective Keratitis

The cornea is at risk of infection when there is disruption of the defense mechanisms, which can be due to various local and systemic factors (Table 1) [5-13]. A systematic approach of infective keratitis in a patient (Fig. 1) not only helps establishing the correct diagnosis but also guides the further management of the patient.

Clinical History and Examination

A detailed clinical history is necessary, which includes the duration of disease, any
history of trauma, lacrimal sac infection, conjunctivitis, contact lens wear, or ocular surface disorder.

**Table 1.** Factors disrupting natural defense mechanism of eye

| Local                                                                 | Systemic                                                                 |
|---------------------------------------------------------------------|--------------------------------------------------------------------------|
| Trauma to intact epithelium [5]                                     | Immunodeficient states [12]                                              |
| Contact lens wear [6,7]                                             | • HIV-AIDS                                                               |
| Eyelid-Entropion, Ectropion, Adnexal Infection                      | • Malignancy                                                             |
| Neurotrophic disease                                               | • Drug induced                                                           |
| Bullous keratopathy [8]                                            | • Connective tissue disorders like Rheumatoid arthritis (adversely affect corneal wound healing) |
| Ocular Surface Disease [9,10]                                      | • Diabetes                                                               |
| Dacrocystitis [11]                                                 | • Measles, malnutrition and diarrhea [13]                                |
| Topical medications - e.g. steroid                                 |                                                                          |

- Intraocular pressure,
- Any ocular surface disorders,
- Ultrasonography for posterior segment to rule out endophthalmitis.

**Documentation**

Documentation of keratitis is very important for management, follow up and assessment of therapy (Fig. 2). Table 2 provides the color-coding for corneal diagrams [14]. The ulcer needs to be graded as mild, moderate or severe depending on its characteristics (Table 3) and its course from infiltration to healing needs to be documented (Table 4) [15].

![Fig. 1 Slit Lamp photo of a patient presenting with infective keratitis](image1.png)

![Fig. 2 Clinical documentation with the help of color-coding](image2.png)
Table 2. Color Coding for documentation

| Condition                      | Color   |
|--------------------------------|---------|
| Epithelial Defect              | Green   |
| Stromal Edema                  | Blue    |
| Epithelial Edema               | Blue circle |
| Infiltrate                     | Yellow  |
| Corneal Scar                   | Grey    |
| Blood Vessels                  | Red (Complete lines) |
| Ghost Vessels                  | Red (Dotted lines) |
| Keratic Precipitates (KP)      | Yellow  |
| Pigments on endothelium        | Brown   |

Table 3. Grading of corneal ulcer

| Size   | Severity |
|--------|----------|
| <2mm   | Mild     |
| 2.5mm  | Moderate |
| >5mm   | Severe   |

| Depth  | Severity |
|--------|----------|
| 20%    | Mild     |
| 20-50% | Moderate |
| >50%   | Severe   |

| Infiltrate     | Severity |
|----------------|----------|
| Superficial    | Mild     |
| Mid-stromal    | Moderate |
| Deeper         | Severe   |

| Sclera         | Severity |
|----------------|----------|
| Not involved   | Mild     |
| Not involved   | Moderate |
| May be involved | Severe |

Table 4. Stages of keratitis

| Stage of progressive infiltration | Stage of active ulceration | Stage of regression | Stage of cicatization |
|-----------------------------------|----------------------------|---------------------|-----------------------|
| Adherence and entry of organism   | Necrosis and sloughing of epithelium, basement membrane, stroma | Induced by natural host immunity and treatment | Necrotic stroma replaced by scar tissue |
| Resultant destruction and necrosis of involved tissue | Margin and floor show grey infiltration and sloughing | Improvement in signs and symptoms Infiltrate decreases in size | Vessels regress completely or residual ghost vessels seen after healing |

Microbiological Workup

A good microbiological evaluation of infective keratitis is invaluable for a correct diagnosis, appropriate therapy and may improve the chances of a successful clinical outcome. Light microscopy and culture methods are commonly employed. Corneal scraping is performed at the slit-lamp under topical anesthesia. Proparacaine 0.5% eye drops should be preferred to lignocaine as it is less bactericidal [16,17]. A 26 or a 23-gauge needle, Bard Parker No. 15 blade or a Kimura spatula may be used. Any loose mucus or debris should be wiped away first. Carefully, the leading edge and the base of the ulcer are scraped. The material is transferred onto slides, at least two in number, for Gram stain and KOH. A circular mark with a pencil can be placed around the collected sample on the reverse side of the slide. In the same way, material is transferred to the culture media. If the patient is instilling several medications, it is preferable to stop antimicrobials for 24 hours and then scrape under close follow up.

Microbiological staining

Gram’s stain: Differentiates bacteria into two major groups, based on their ability to retain the dye crystal violet [18]. Can identify Acanthamoeba and Nocardia as well (Fig. 3).

KOH wet mount - Detecting fungus is very important so that indiscriminate use of antifungals is avoided as these medications are keratotoxic. Due to high sensitivity and specificity of KOH mount for fungus, this becomes the most important single test if there...
is lack of resources [19]. It is 92% sensitive and 96% specific for fungus [19]. It can also identify Acanthamoeba & Nocardia (Fig. 4).

Fig. 4 10% KOH wet mount used for diagnosis

The other specific stains not routinely performed are:
- **Giemsa stain** - It helps identify inclusion bodies in viral and chlamydia infections. It can also help differentiate bacteria and fungi, identify cysts and trophozoites of Acanthamoeba [20].
- **Ziehl-Neelsen stain** - for Mycobacteria, Actinomyces, and Nocardia [21].

**Culture Medias** - Bacterial and Fungal colonies have specific characteristics on culture that help in their identification (Fig. 5).

![Table of culture medias](image)

| Blood agar | Chocolate agar | Nutrient agar |
|------------|----------------|---------------|
| Staphylococcus in BA | Pseudomonas in CA | Nutrient agar without any growth |
| Sabouraud dextrose agar | Thioacetate broth | LJ medium |
| Aspergillus niger in SOA | Fungus in thioacetate broth | Mycobacteria on LJ medium |

Fig. 5 Various culture medias used in microbiology workup

- Blood Agar - for isolation of aerobic bacteria at 35°C, and fungi and Nocardia at room temperature.
- Chocolate Agar - for facultative organisms such as Haemophilus, Moraxella and Neisseria.
- Sabouraud Dextrose Agar - is a non-selective medium for opportunistic fungal pathogens.
- Non-nutrient Agar with E. Coli overlay for Acanthamoeba.
- Thioglycollate broth - facilitates the isolation of anaerobes.
- Lownstein Jensen (LJ) medium - for Mycobacteria.

**Clinical Features**

**Bacterial keratitis**

Bacterial keratitis is a common form of infective keratitis with incidence ranging from 50 to 60% [22] and Staphylococcus spp., Streptococcus spp. Pseudomonas being the frequent isolates.

Patients usually complain of rapid onset of pain, photophobia, and decreased vision. An associated history of ocular trauma may be present. Biomicroscopic examination may reveal features such as ulceration of epithelium, suppurative stromal infiltration with surrounding edema, anterior chamber reaction with or without hypopyon and mucopurulent exudate.

Keratitis caused by Pseudomonas Aeruginosa, a Gram-negative organism is more fulminant and is associated with a worse visual prognosis than other bacterial pathogens [23]. Sudden onset and rapid progression of ocular pain is associated with epithelial defect and stromal infiltrate, which often assumes a ring configuration. Stromal necrosis and progressive thinning may be associated. Contact lenses are a common risk factor for keratitis.

**Fungal Keratitis**

Fungal keratitis has an incidence of 6 to 30%, with the common isolates being Aspergillus, Fusarium, Penicillium [24-28]. Fungal keratitis has certain special characteristics that may help differentiating it from bacterial Keratitis - feathery borders and
indistinct edges [29], a fixed hypopyon [30], immune rings, endothelial plaques and a posterior corneal abscess [31].

Parasitic Keratitis

Acanthamoeba keratitis is a chronic, primarily contact lens-related infection caused by a free-living amoeba found ubiquitously in water and soil [32,33]. Acanthamoeba exists in two forms - trophozoites and cyst. Potential risk factors for Acanthamoeba keratitis are damage to the corneal epithelium, contact lenses, contaminated water, or solution and host susceptibility [20]. Clinical features of Acanthamoeba keratitis are severe ocular pain, epithelial irregularity and dendriform pattern, severe anterior and posterior scirrhus, ring shaped stromal infiltrate, anterior uveitis, persistent or recurrent epithelial erosion, radial keratoneuritis, disciform keratitis [20]. Culturing the specimen on a confluent lawn of the E. coli plated on non-nutrient agar is the microbiological diagnostic technique.

Viral Necrotizing Keratitis

It is a rare manifestation of HSV that results from direct viral invasion of the corneal stroma. The clinical findings are necrosis, ulceration, and dense infiltration of the stroma with an overlying epithelial defect. The combination of replicating virus and severe host inflammatory response leads to destructive intrastromal inflammation [34]. The clinical findings resemble those of infective keratitis secondary to microbial invasion. Therefore, necrotizing viral stromal keratitis must be considered a differential diagnosis.

Atypical organisms

Acid Fast Bacilli Keratitis

Nocardia are aerobic, gram-positive, non-motile, and branched filamentous bacteria [21]. Trauma is the most common predisposing factor. The clinical picture of nocardia keratitis usually consists of superficial patchy infiltrates, which may be arranged in a wreath pattern [21]. Presence of gram-positive, branching, beaded filaments that stain with 1% acid-fast stain (using 1% sulfuric acid, modified Kinyoun’s method) is suggestive of nocardia infection. Nocardia grow on commonly used media as tiny, white, dry colonies [35]. Non-tuberculous or atypical mycobacteria are aerobic, non-spore forming, non-motile bacilli [36]. Infection can occur after corneal trauma, any anterior segment surgery, or use of contact lenses. Keratitis often manifests as a relatively indolent, recalcitrant stromal infection, which usually develops 2 to 3 weeks after trauma or surgery [37]. The disease may wax and wane over a period of several months. Pain is variable. The stromal infiltrates may show feathered edges, satellite lesions, crystalline keratopathy, or a ring pattern. A “cracked windshield” corneal infiltrate is virtually diagnostic [36]. The Fite Ferraco stain uses a gentler acid wash than the Ziehl-Nielsen technique, thus allowing the bacilli to better retain their stain [37]. Positive cultures on Lowenstein-Jensen agar medium constitute a definitive diagnosis.

Management

Injective Keratitis patients can be managed as outpatients. The choice of specific antimicrobial agent hits the bull’s eye. Treatment is initiated based on smears, without waiting for the results of culture and sensitivity. Initial empirical therapy for bacterial keratitis involves frequent instillation of broad-spectrum antibiotic drops. Many prefer the combination mode of therapy, wherein a cephalosporin is combined with an aminoglycoside. The cephalosporin covers the gram-positive cocci and some gram-negative rods, and the aminoglycoside, the gram-negative ones [38,39]. Commonly, 5% cephaazolin is combined with 1.3% tobramycin. Monotherapy, using only one fluoroquinolone, is also effective. Ciprofloxacin 0.3%, Ofloxacin 0.3%, Gatifloxacin 0.3%, or Moxifloxacin 0.5% may be used [40,41]. However, monotherapy is usually reserved for keratitis, which is not severe or does not involve the visual axis.

Whatever the chosen strategy, monotherapy or combination therapy, drugs are started intensively. Initially, the loading dose is preferred followed by the hourly administration of topical antibiotic for the first 48 hours. These patients need a close follow up with corneal drawing depicting accurate measure of infiltrate, epithelial defect, and height of hypopyon.
Modification of drug therapy is required only if there is no response or worsening of the clinical signs on treatment. The drugs should not be changed if a favorable clinical response is seen, even if microbiological results show a resistant pathogen.

The use of topical corticosteroids as adjunctive therapy in the treatment of bacterial corneal ulcers has been debated extensively during the past few decades. The Steroids for Corneal Ulcers Trial (SCUT) conducted between 2006 and 2010 concluded that adjunctive topical corticosteroid use does not improve 3-month vision in patients with bacterial corneal ulcer [42].

Natamycin 5% ophthalmic suspension is the initial drug of choice for most cases of fungal keratitis. As in bacterial infections, dosing is started on an hourly basis, and then reduced as the ulcer started to resolve. For Candida infections, Amphoterin C 0.15% or Fluconazole 0.3% are effective. Voriconazole is a newer antifungal agent, an azole, with a broader spectrum of antifungal activity, and a lower minimum inhibitory concentration [43]. However, it is not recommended as monotherapy in filamentous keratitis. According to Mycotic Ulcer Treatment Trial (MUTT), Natamycin was associated with significantly better clinical and microbiological outcomes than voriconazole for smear-positive filamentous fungal keratitis [44].

Fungal keratitis is slower to respond than bacterial, taking several weeks [45]. Therefore, the duration of treatment is more prolonged. Oral antifungals are indicated in large or deep ulcers, scleral extension, or endophthalmitis. Fluconazole and Ketoconazole are the most widely used systemic antifungals. Two to three weekly liver function test assessments should be performed when a patient is kept on systemic antifungals.

Corneal epithelial debridement, every 24 to 48 hours, should be performed in fungal keratitis. It serves to debulk the cornea of necrotic debris and to enhance the penetration of topical antifungals. Therapeutic penetrating keratoplasty should be performed if medical therapy fails. Nearly a third of patients were found to fail medical therapy [46].

For Acanthamoeba keratitis, Chlorhexidine (0.02%), Polyhexanide biguanide (0.02%), Propamidine isethionate (0.1%) or Hexamidine (0.1%) are found to be effective [20]. In addition to topical medications, oral itraconazole (200 mg/day) may be added.

For Necrotizing Viral Stromal Keratitis, therapeutic aqueous humor levels can be achieved with oral Acyclovir in a dose of 400 mg five times daily for 10 weeks and ointment Acyclovir 5 times a day for 2 weeks. Diluted steroids can be started after 2 weeks of treatment in tapering doses under careful observation [34]. Topical cycloplegics should be administered to relieve pain from ciliary spasm and prevent the formation of posterior synechiae. Homatropine, Atropine eye drops, or ointment may be given. A secondary glaucoma may accompany the anterior segment inflammation requiring topical 0.5% timolol twice daily or even systemic acetazolamide.

Management of Keratitis caused by atypical organisms

Nocardia Keratitis - Therapy with trimethoprim-sulfamethoxazole and amikacin is effective [35].

Atypical mycobacteria Keratitis - Topical fortified amikacin (14-100 mg/ml) is the drug of choice. They may also show varying degrees of susceptibility to other drugs like fluoroquinolones, aminoglycosides, and tetracycline family [37].

Assessment of Therapy

There are specific biomicroscopic signs indicating the healing response in Keratitis. There is blunting of the perimeters of the infiltrate, reduction of the density of the suppuration with reduction in cellular infiltrate and edema in the surrounding stroma. Reduction in anterior chamber inflammation is noted with progressive re-epithelization and loss of the feathery perimeter of the stromal inflammation.

If the keratitis is progressing then admission of the patient is advisable to ensure compliance. If resistance to the primary therapy is noted the microbiology results need to be reviewed and change to appropriate antimicrobials is advocated. Corneal biopsy is indicated and other possible causes must be investigated if the results are inconclusive.
Surgical therapy

Tissue adhesives
Cyanoacrylate glue is indicated to manage perforations less than 3mm in size, and impending perforations and descemetocele. After thin glue application, bandage contact lens is placed over cornea.

Therapeutic Keratoplasty
Progressive ulceration, non-response to therapy or large areas of perforation requires a corneal graft (Fig. 6 a-d). The corneal button that is removed should be sent for microbiological evaluation. Also, the diameter of the trephination should be large enough to include 1mm of the surrounding normal cornea. Smaller areas of keratitis, requiring surgical treatment can be managed with patch grafts.

Fig. 6 Bacterial keratitis leading to impending perforation treated with limbus-to-limbus keratoplasty (A) shows the pre operative picture (B) shows the postoperative picture (C) Non resolving fungal keratitis (D) therapeutic keratoplasty done for the same patient

Conclusion

A meticulous clinical examination of a patient of infective keratitis goes a long way in arriving at the correct diagnosis. Appropriately, targeted antimicrobial therapy backed by microbiological investigations is the first step in the management of the condition. Keeping a bird’s eye view on progression, modifying therapy if required, and not delaying surgical intervention, if deemed necessary, is the key to a successful outcome.
Acknowledgements
None.

Financial Disclosures
Nil.

Conflict of Interest
None declared for any author.

References
1. Turvey TA, Golden BA. Orbital Anatomy for the Surgeon. Oral Maxillofac Surg Clin North Am. 2012; November; 24(4):525-536.
2. McClellan KA. Mucosal defense of the outer eye. Surv Ophthalmol. 1997; 42:233-46.
3. Bolanos-Jimenez R, Navas A, Lopez- Lizarraga EP et al. Ocular surface as barrier of innate immunity. Open Ophthalmol J 2015; 9:49-55.
4. Dua HS, Gomes JA, Donoso LA et al. The ocular surface as part of the mucosal immune system: conjunctival mucosa-specific lymphocytes in ocular surface pathology. Eye. 1995; 9:261-267.
5. Ogawa GSH, Hyndriuk RA. In: Smolin G, Thoft RA (Eds). The Cornea Scientific Foundations and Clinical Practice. Bacterial Keratitis and Conjunctivitis. 3rd ed., Chapter 5, Philadelphia, Lippincott Williams and Wilkins, 125.
6. Najjar DM, Aktan SG, Rapuano CJ et al. Contact lens-related corneal ulcers in compliant patients. Am J Ophthalmol 2004; 137:170-2.
7. Young AL, Leung AT, Cheng LL et al. Orthokeratolgy lens-related corneal ulcers in children: A case series. Ophthalmology. 2004; 111:590.
8. Luchs JI, Cohen EJ, Rapuano CJ et al. Ulcerative keratitis in bullous keratopathy. Ophthalmology. 1997; 104:816-22.
9. Vajpayee RB, Gupta SK, Bareja U et al. Ocular atopy and myotic keratitis. Ann Ophthalmol. 1990; 22:369-72.
10. Sridhar MS, Garg P, Das S et al. Infectious keratitis in climatic droplet keratopathy. 2000; 14:455-8.
11. Aasuri MK, Reddy MK, Sharma S et al. Co-occurrence of pneumococal keratitis and dacryocystitis. Cornea. 1999; 18:273-6.
12. Aristimuno B, Nirankari VS, Hemady RK et al. Spontaneous ulcerative keratitis in immunocompromised patients. Am J Ophthalmol. 1993; 115:202-8.
13. Vajpayee RB, Ray M, Panda A et al. Risk factors for pediatric presumed microbial keratitis: A case control study. Cornea. 1999; 18:565-9.
14. Bron AJ. A simple scheme for documenting corneal disease. Brit J Ophthal. 1973; 57:629-34.
15. Harrison SM. Grading corneal ulcers. Ann Ophthalmol. 1975; 7:537-9.
16. Kaufman HE, Baron BA, McDonald MB, Kaufman SC. The Cornea, 2nd ed., Boston, Massachusetts, Butterworth-Heinemann.
17. Huang AJW, Wichiensi P, Yang MC. Bacterial keratitis: In: Krachmer JH, Mannis MJ, Holland EJ (Eds). Cornea Fundamentals, Diagnosis and Management, 2nd edition, 2005; 1:1005-34.
18. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979; 24:97,105-16.
19. Vajpayee RB, Angra SK, Sandramouli S et al. Laboratory diagnosis of keratomycosis: comparative evaluation of direct microscopy and culture results. Ann Ophthalmol. 1993; 25:68-71.
20. Garg P, Kalra P, Joseph J. Non contact lens related Acanthamoeba keratitis. Indian J Ophthalmol. 2017; 65:1079-86.
21. Hirst LW, Harrison K, Merz WG et al. Nocardia asteroids keratitis. Br J Ophthalmol. 1979; 63:449-54.
22. Ranjini CY, Waddeppally VV. Microbial Profile of corneal ulcers in a tertiary care hospital in South India. J Ophthalmic Vis Res. 2016; 11:363-367.
23. Vazirani J, Wurity S, Ali MH. Multidrug- Resistant Pseudomonas aeruginosa Keratitis: Risk Factors, Clinical Characteristics and Outcomes. Ophthalmology. 2015; 122:2110-4.
24. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am J Ophthalmol. 1980; 90:38-47.
25. Panda A, Sharma N, Das G et al. Myotic keratitis in children: epidemiologic and microbiologic evaluation. Cornea. 1997; 16:295-299.
26. Bharathi MJ, Ramakrishnan R, Vasu S et al. Epidemiological characteristics and laboratory diagnosis of fungal keratitis: a three-year study. Indian J Ophthalmol. 2003; 51:315-321.
27. Gopinathan U, Garg P, Fernandes M et al. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea. 2002; 21:555-559.
28. Garg P, Gopinathan U, Choudhary K et al. Keratomycosis: clinical and microbiologic experience with Dematiaceous fungi. Ophthalmology. 2000; 107:574-580.
29. Srinivasan M, Gonzales CA, George C et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol. 1997; 81:965-71.
30. Hagan M, Wright E, Newman M, Dolin P, Johnson G. Causes of suppurative keratitis in Ghana. Br J Ophthalmol. 1995; 79:1024-8.
31. Srinivasan R, Kanungo R, Goyal JL. Spectrum of Oculomycosis in South India. Acta Ophthalmol. 1991; 69:744-9.
32. Tu EY, Joslin CE, Sugar J et al. Prognostic factors affecting visual outcome in Acanthamoeba keratitis. Ophthalmology. 2008; 115:1998-2003.
33. Duguid IG, Dart JK, Morlet N et al. Outcome of Acanthamoeba keratitis treated with polyhexamethylene biguanide and proamidine. Ophthalmology. 1997; 104:1587-1592.
34. Dutt S, Acharya M, Gour A et al. Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis. Indian J Ophthalmol. 2016; 64:292-5.
35. Lalitha P, Tiwari M, Prajna NV et al. Nocardia Keratitis. Cornea. 2007; 26:255-259.
36. Turner L. Atypical mycobacterial infections in ophthalmology. Trans Am Ophthalmol Soc. 2013; 68:667–729.

37. Huang SC, Soong HK, Chang JS et al. Non-tuberculous mycobacterial keratitis: a study of 22 cases. Br J Ophthalmol. 1996; 80:962–968.

38. Das S, Sheorey H, Taylor HR, Vajpayee RB. Association between cultures and contact lens and corneal scraping in contact lens related microbial keratitis. Arch Ophthalmol. 2007; 125:1182-5.

39. Huang AJW, Wichiensin P, Yang MC. Bacterial keratitis. Chapter 81. In: Krachmer JH, Mannis MH, Holland EJ (Eds). Cornea: Fundamentals, Diagnosis and Management, NY, 2005, 1005-33.

40. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double masked, randomized, controlled trial with conventional dual therapy: The Ofloxacin Study Group. Ophthalmology. 1997; 104:1902-9.

41. Constantinou M, Daniell M, Snibson GR et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: A randomized clinical trial. Ophthalmology. 2007; 114:1622-9.

42. Srinivasan M, Mascarenhas J, Rajaraman R et al. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 2012; 130:143–150.

43. Shah KB, Wu TG, Wilhelmus KR et al. Activity of Voriconazole against corneal isolates of Scedosporium apiospermum. Cornea. 2003; 22:33-6.

44. Prajna NV, Krishnan T, Mascarenhas J et al. Mycotic Ulcer Treatment Trial G The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs. voriconazole. JAMA Ophthalmol. 2013; 131:422–429.

45. Wilson LA, Ajello L. Agents of oculomycosis: fungal infections of eye. In: Collier L, Balows A, Sussman (Eds): Topley and Wilson’s Microbiology and microbial infections, 9th edition, London, Medical Mycology Arnold, 1998; 4:525-67.

46. Portnoy SL, Insler MS, Kaufman HE. Surgical management of corneal ulceration and perforation. Surv Ophthalmol. 1989; 34:47-58.